Browsing Tag
The Lancet
3 posts
Breakthrough results: Intensity Therapeutics’ INT230-6 delivers strong survival and immune response in phase 1/2 cancer trial
Find out how Intensity Therapeutics’ INT230-6 achieved 11.9-month survival and immune activation in metastatic cancer—read what this means for biotech investors.
Resmed earnings soar—Is this sleep tech giant the next big health stock to watch?
Find out how Resmed’s Q3 FY25 results and stock surge signal strength in the sleep tech market. Explore the bullish sentiment and investor strategy.
MeiraGTx’s rAAV8.hRKp.AIPL1 shows remarkable efficacy in treating severe retinal dystrophy
A gene therapy developed by MeiraGTx Holdings plc has demonstrated remarkable success in restoring vision to children born…